Keryx Biopharma (KERX), AEterna Zentaris (AEZS) Get a Reality Check
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
After zooming higher Monday, biotech stocks Keryx Biopharma (Nasdaq: KERX) and AEterna Zentaris (Nasdaq: AEZS) are both lower in pre-open trading Tuesday as there is now questions about analysis of the recent Seeking Alpha article which said FDA approval is "practically a done deal".
"The credibility of the author, Jeremy Richards, and the veracity of claims and statements made by him, couldn't be verified by anyone at his purported investment firm, the drug companies and Seeking Alpha," TheStreet.com's Adam Feuerstein writes Tuesday.
Keryx Biopharma is down 6 percent today after jumping 33 percent Monday and AEterna Zentaris is down 12 percent after ramping 23 percent higher Monday.
"The credibility of the author, Jeremy Richards, and the veracity of claims and statements made by him, couldn't be verified by anyone at his purported investment firm, the drug companies and Seeking Alpha," TheStreet.com's Adam Feuerstein writes Tuesday.
Keryx Biopharma is down 6 percent today after jumping 33 percent Monday and AEterna Zentaris is down 12 percent after ramping 23 percent higher Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
